Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
EPAM Epam Systems Inc
ISLE Isleworth Healthcare Acquisition Corp
TRMD Torm PLC
THC Tenet Healthcare Corp
BKCC BlackRock Capital Investment Corp
VIR Vir Biotechnology Inc
CBH Virtus Convertible & Income 2024 Target Term Fund
PSX Phillips 66
RGT Royce Global Value Trust
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Price
Delayed
$79.62
Day's Change
0.37 (0.47%)
Bid
--
Ask
--
B/A Size
--
Day's High
79.70
Day's Low
76.93
Volume
(Heavy Day)

Today's volume of 25,863 shares is on pace to be much greater than INCY's 10-day average volume of 1,337,595 shares.

25,863
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.